在高正常浓度血管性血友病因子下增强重症监护室需血小板输注患者的血小板止血效果——Will-Plate随机对照试验方案
Will-Plate研究是一项研究者发起的单中心双盲随机对照试验,纳入120例需血小板输注的危重症患者,评估在血小板输注基础上联合平衡血管性血友病因子(vWF,1:1 vWF与FVIII)能否减少血液制品输注需求。主要结局为各组新鲜冰冻血浆和红细胞输注数量;样本量按检测Wilate®较安慰剂在2天内后续输注血制品数量减少50%计算。
要点
- 研究假设:在血小板基础上加用平衡vWF可减少血制品输注需求。
- 主要结局:各组新鲜冰冻血浆和红细胞输注数量。
- 样本量按检测Wilate®较安慰剂2天内血制品输注减少50%计算。
核心结论
- 研究假设为在血小板基础上加用平衡vWF相比单纯输注血小板可减少血制品总体输注需求。
研究设计与样本
- 研究者发起的单中心双盲随机对照临床试验,纳入120例需血小板输注的危重症患者。
- 研究在重症监护室收治的严重出血患者中开展。
主要发现
- 原文为试验方案,未报告研究结果。
关键数值与推荐
- 主要结局为各组新鲜冰冻血浆和红细胞输注数量。
- 次要结局包括研究药物处理后48小时内输注血小板浓缩物数量、48小时内失血量、ICU和住院时间、因出血控制再次手术次数、ICU死亡率、住院死亡率、30天死亡率和1年死亡率。
- 样本量按检测Wilate®较安慰剂在2天内后续输注血制品数量减少50%计算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: von Willebrand Factor (vWF) is a key protein mediating platelet adhesion on the surface of damaged endothelia. To the best of our knowledge, no trial exists that investigated the effect of platelet transfusion in combination with the administration of balanced vWF in severe blood loss, despite being widely used in clinical practice. The Basel Will-Plate study will investigate the impact of the timely administration of balanced vWF (1:1 vWF and FVIII) in addition to platelet transfusion on the need for blood and coagulation factor transfusion in patients admitted to the intensive care unit (ICU) who suffer from severe bleeding. The study hypothesis is based on the assumption that adding balanced vWF to platelets will reduce the overall need for transfusion of blood products compared to the transfusion of platelets alone. METHODS AND ANALYSIS: The Will-Plate study is an investigator-initiated, single-centre, double-blinded randomised controlled clinical trial in 120 critically ill patients needing platelet transfusion. The primary outcome measure will be the number of fresh frozen plasma (FFP) and red blood cell (RBC) transfusions according to groups. Secondary outcome measures include the number of platelet concentrates transfused within the first 48 h after treatment of study medication, quantity of blood loss in the first 48 h after treatment with the study medication, length of stay in ICU and hospital, number of revision surgeries for haemorrhage control, ICU mortality, hospital mortality, 30-day mortality and 1-year mortality. Patients will be followed after 30 days and 1 year for activities of daily living and mortality assessment. The sample size was calculated to detect a 50% reduction in the number of blood products subsequently transfused within 2 days in patients with Wilate® compared to placebo. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of Northwestern and Central Switzerland and will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) and all national legal and regulatory requirements. The study results will be presented at international conferences and published in a peer-reviewed journal. TRIALS REGISTRATION: ClinicalTrials.gov NCT04555785. PROTOCOL VERSION: Clinical Study Protocol Version 2, 01.11.2020. Registered on Sept. 21, 2020.
引用
- Herrmann G, Blum A, Bolliger D, et al. Enhancement of the haemostatic effect of platelets in the presence of high normal concentrations of von Willebrand factor for critically ill patients needing platelet transfusion-a protocol for the will-plate randomised controlled trial. Trials. 2023. PMID: 36670471. doi:10.1186/s13063-022-06876-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。